Nanomedicine Approach Could Offer New Way to Target HER2+ Breast Cancer

Novel research suggests that using a nano-molecularly imprinted polymer may offer a unique and effective way to treat HER2+ breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news

Related Links:

CONCLUSION: Breast cancer molecular subtype did not influence biopsy recommendations, positive predictive values, or surgical approaches. Only true positive biopsies increased the mastectomy rate. PMID: 32619774 [PubMed - indexed for MEDLINE]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Clin Imaging Source Type: research
Authors: Park SK, Park JA, Yang SY, Shin JY, Koh H Abstract Objectives: Recognizing the value of anticancer treatments based on progression-free survival and overall survival may help decision making in healthcare policy. We aimed to measure and compare the impact of disease progression and terminal state prior to death on healthcare costs in HR+, HER2- ABC patients.Methods: We conducted a retrospective study using Korean nationwide health insurance claims database between 9/1/2012-8/31/2017. The impact of disease progression was estimated by measuring the average incremental monthly cost per patient during 1 year ...
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
AbstractBreast cancer (BC) is the most common female cancer and the second cause of death among women worldwide. The 5-year relative survival rate recently improved up to 90% due to increased population coverage and women ’s attendance to organised mammography screening as well as to advances in therapies, especially systemic treatments. Screening attendance is associated with a mortality reduction of at least 30% and a 40% lower risk of advanced disease. The stage at diagnosis remains the strongest predictor of re currences. Systemic treatments evolved dramatically over the last 20 years: aromatase inhibitors...
Source: Insights into Imaging - Category: Radiology Source Type: research
Authors: Ducharme M, Lapi SE Abstract Breast cancer continues to be the most lethal cancer type in women and one of the most diagnosed. Understanding Breast cancer receptor status is one of the most vital processes for determining treatment options. One type of breast cancer, human epidermal growth factor receptor 2 (HER2) positive, has approved receptor-based therapies including trastuzumab and pertuzumab that can significantly increase the likelihood of survival. Current methods to determine HER2 status include biopsies with immunohistochemical staining and/or fluorescence in situ hybridization. However, positron...
Source: Molecular Imaging - Category: Radiology Tags: Mol Imaging Source Type: research
Conclusions: Patients with metastatic breast cancer should perform re-biopsy to clarify the receptor status of the first metastatic lesions, which may provide clinicians valuable evidence to conduct treatments with higher precision.Oncol Res Treat
Source: Oncology Research and Treatment - Category: Cancer & Oncology Source Type: research
Background and Objectives: The influence of age at diagnosis of breast cancer upon the prognosis of patients with different immunohistochemical (IHC)-defined subtypes is still incompletely defined. Our study aimed at examining the association of age at diagnosis and risk of breast cancer-specific mortality (BCSM).Methods: 172,179 eligible breast cancer patients were obtained for our study cohort using the Surveillance, Epidemiology, and End Results database from 2010 to 2015. Patients were classified into four IHC-defined subtypes according to their ER, PgR, and HER2 status. Kaplan–Meier plots were used to describe B...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
The fasting mimicking diet emerged from efforts to better define the dose-response curve for beneficial effects resulting from a reduced calorie intake. Fasting is beneficial, calorie restriction is beneficial, but where are the dividing lines? How much food can one eat and still obtain near all of the benefits of fasting? As a result of this work, the fasting mimicking diet has undergone clinical testing in cancer patients. Numerous benefits have been demonstrated, and the paper here is an example of the type. In this human trial, fasting mimicking reduced the negative short term impact of chemotherapy on health, and, fur...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
Contributors : M Schmidt ; M GehrmannSeries Type : Expression profiling by arrayOrganism : Homo sapiensInterferons are crucial for adaptive immunity and play an important role in the immune landscape of breast cancer. Using microarray-based gene expression analysis, we examined the subtype specific prognostic significance of interferon- γ (IFN-γ) as a single gene as well as an IFN-γ signature covering the signaling pathway in 461 breast cancer patients. Prognostic significance of IFN-γ as well as the IFN-γ signature for metastasis-free survival (MFS) were examined using Kaplan Meier as well as...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
los EM, Parker JS Abstract PURPOSE: Predicting prognosis in HR+/HER2-negative MBC might be clinically useful; however, no validated prognostic biomarkers exist in this setting to date. EXPERIMENTAL DESIGN: In phase III, EGF30008 trial, 484 patients with HER2-negative MBC who received letrozole and placebo or lapatinib were selected. PAM50 data, ECOG PS, visceral disease, number of metastasis, biopsy type, and age were evaluated. A progression-free survival (PFS) Cox model was evaluated. The final model (PAM50MET) with a prespecified cutoff was validated in patients (n=261) with HR+/HER2-negative aBC from BOLE...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Patients with HR+, HER2- breast cancer at high risk of early recurrence on endothelial therapy could highly improve their invasive disease-free survival with adjuvant abemaciclib, a new trial shows.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Nanotechnology